N-乙酰半胱氨酸预防顺铂所致听力损失:系统综述与Meta分析
该系统综述与Meta分析纳入7项研究共217例患者,评估全身或鼓室注射N-乙酰半胱氨酸(NAC)预防顺铂所致听力损失(CIHL)的疗效。结果显示,与安慰剂相比,两种给药途径的NAC在CIHL预防上均无显著差异(全身给药RR 0.80,95%CI 0.54-1.19,P=.28;鼓室注射RR 0.89,95%CI 0.51-1.54,P=.67),0.5-8 kHz各组间无显著差异;定性分析提示10和12 kHz超高频可能倾向耳保护。结论认为当前证据未显示NAC在标准临床听力图范围内有效,需更大样本研究证实。
要点
- 全身或鼓室注射NAC与安慰剂相比,在预防CIHL上均无显著差异。
- 0.5-8 kHz各频率组间无显著差异,10和12 kHz定性分析提示倾向耳保护。
- 作者认为当前证据未显示NAC在标准临床听力图范围内有效,需更大样本研究。
核心结论
- 作者认为,无论给药途径如何,当前已发表证据未显示NAC在标准临床听力图范围内可有效预防CIHL。
- 作者指出需更大样本的研究来证实上述发现。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Web of Science、Clinicaltrials.gov和Cochrane Library。
- 纳入报告全身或鼓室注射NAC预防CIHL的研究,共7项研究、217例患者。
- 217例患者中175例接受NAC全身给药,其余接受NAC鼓室注射。
主要发现
- 全身给药NAC与安慰剂相比,CIHL预防无显著差异(RR 0.80;95%CI 0.54-1.19;P=.28)。
- 鼓室注射NAC与安慰剂相比,CIHL预防无显著差异(RR 0.89;95%CI 0.51-1.54;P=.67)。
- 0.5至8 kHz各组间未发现显著差异。
- 定性分析提示10和12 kHz超高频有耳保护倾向。
关键数值与推荐
- 结局指标包括听力损失事件的存在及顺铂治疗后0.5至12 kHz听力阈值变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需更大样本的研究来证实上述发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cisplatin is an effective antineoplastic drug used worldwide in the treatment of various malignancies. However, it is associated with side effects, including cisplatin-induced hearing loss (CIHL). N-acetylcysteine (NAC) has been suggested as a promising drug to prevent or reduce cisplatin-derived ototoxicity. To evaluate the evidence supporting the efficacy of NAC in preventing CIHL, we conducted a systematic review and meta-analysis of the literature. DATA SOURCES: A systematic search was conducted on PubMed, Embase, Web of Science, Clinicaltrials.gov, and Cochrane Library. REVIEW METHODS: Articles reporting the administration of systemic or transtympanic injection of NAC for CIHL prevention were considered. The outcomes of interest included the presence of hearing loss events and changes in hearing thresholds at 0.5 through 12 kHz following cisplatin treatment. RESULTS: A total of 7 studies involving 217 patients met inclusion criteria. Of these patients, 175 received systemic administration of NAC, and the remaining received transtympanic injection of NAC. No significant differences were found in CIHL prevention between the use of either systemic or transtympanic NAC administration compared to placebo (risk ratio [RR] 0.80; 95% confidence interval [CI] 0.54-1.19; P = .28, and RR 0.89; 95% CI 0.51-1.54; P = .67, respectively). No significant differences were found at 0.5 to 8 kHz between groups. Qualitative analyses suggested a tendency to otoprotection in ultra-high frequencies (10 and 12 kHz). CONCLUSION: Our findings suggest that, regardless of administration route, current published evidence does not show that NAC is effective in preventing CIHL in the standard clinical audiogram range. Further studies with larger samples are needed to confirm our findings. LEVEL OF EVIDENCE: I.
引用
- Plane J, Cabral TDD, Knoll RM, et al. N-acetylcysteine for the Prevention of Cisplatin-Induced Hearing Loss: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2025. PMID: 40323204. doi:10.1002/ohn.1272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。